3-(2-Methoxyphenyl)azetidin-3-ol hydrochloride | 550370-16-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环丁烷
• 英文名称: 3-(2-Methoxyphenyl)azetidin-3-ol hydrochloride
• 英文别名: 3-(2-methoxyphenyl)azetidin-3-ol;hydrochloride
• CAS: 550370-16-6
• 化学式: C10H14ClNO2
• 分子量: 215.67
• InChiKey: GVSLZMZLHHVIGY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.91
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  41.5
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• Lactams as tachkinin antagonists
  申请人：Pfizer Inc.

  公开号：US20040132710A1

  公开（公告）日：2004-07-08

  Compounds of the formula (I): 1 or a pharmaceutically acceptable salt, prodrug, solvate or polymorph thereof, wherein R, R 1 , and Z are as defined herein, are useful in treating or preventing a condition for which an NK 2 antagonist is efficacious.

  公式（I）的化合物：1或其药学上可接受的盐，前药，溶剂化合物或多晶形式，其中R，R1和Z的定义如本文所述，可用于治疗或预防NK2拮抗剂有效的疾病。
• LACTAMS AS TACHYKININ ANTAGONISTS
  申请人：Pfizer Limited

  公开号：EP1456200A1

  公开（公告）日：2004-09-15
• US7060836B2
  申请人：——

  公开号：US7060836B2

  公开（公告）日：2006-06-13
• [EN] LACTAMS AS TACHYKININ ANTAGONISTS<br/>[FR] LACTAMES AGISSANT COMME DES ANTAGONISTES DE LA TACHYKININE
  申请人：PFIZER LTD

  公开号：WO2003051868A1

  公开（公告）日：2003-06-26

  Compounds of the formula (I) or a pharmaceutically acceptable salt, prodrug, solvate or polymorph thereof, wherein: R is heta; R1 is phenyl optionally substituted by one or more substituents; m is 1-4; Z is selected from: a) N(R3)(R4X) wherein X is NR?3R5, OR5, Oaryl1, Ohetb, Ohetc, aryl1, hetb or hetc¿; b) N(R3)Y wherein Y is aryl?1, hetb or hetc¿; and c) a 4-7 membered N containing saturated or partially saturated heterocycle said heterocycle attached to the alkylene link via said nitrogen atom, said heterocycle optionally containing an additional 1-3 groups, each independently selected from C=O, NH, S(O)¿p? and O; optionally, said heterocycle is: (i) spirofused with het?b¿, such that both rings share 1 atom; or (ii) optionally independently substituted by 1-3 groups; wherein R?3 and R6¿ are both independently selected from H and C¿1-6?alkyl; wherein R?4¿ is selected from C¿1-6? alkylene; wherein R?5¿ is selected from C(O)OR3, S(O)¿pR?3, S(O)¿p?aryl?1, C(O)R3¿, and C(O)NR?3R6; hetb¿ is a 4-7 membered heterocycle containing 1-3 heteroatoms, each independently selected from N, O and S, said N being optionally substituted with O, said ring optionally containing 1-2 C=O groups, said ring being saturated or partially saturated, said ring being optionally benzofused, said ring being optionally substituted by 1-3 substituents; heta and hetc are a 5-7 membered aromatic heterocycle containing 1-3 heteroatoms each independently selected from N, O and S, said ring being optionally benzofused, said ring system as a whole being optionally substituted by 1-3 substituents; aryl1 is phenyl or naphthyl, each being optionally substituted by 1-3 substituents; p is 0, 1 or 2; and n is 0-4; are useful in treating or preventing a condition for which an NK¿2? antagonist is efficacious.